多西他赛联合腹腔热灌注化疗加热疗治疗晚期卵巢癌

梁秀菊; 楚慧丽; 王俊; 毕经旺

doi:10.3969/j.issn.1000-8179.20121537

多西他赛联合腹腔热灌注化疗加热疗治疗晚期卵巢癌

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

摘要

摘要:
目的观察多西他赛联合腹腔内顺铂热灌注化疗加热疗治疗晚期卵巢癌的疗效与不良反应。
方法无法手术及复发晚期卵巢癌患者83例，随机分成两组：热疗组42例，行多西他赛静脉化疗后即刻行腹腔内顺铂热灌注化疗并加腹部局部射频热疗；对照组41例，单纯给予多西他赛静脉化疗加腹腔内顺铂热灌注化疗。
结果热疗组和对照组的总有效率分别是81.0%和58.1%，其中总有效率显著提高（P < 0.05），腹水控制率分别为78.3%和66.7%，CA125下降率分别为84.2%和61.5%（P < 0.05），主要不良反应为消化道不良反应及骨髓抑制，无显著性差异。
结论多西他赛联合顺铂腹腔内灌注加热疗明显提高晚期卵巢癌的疗效，不增加不良反应，值得进一步推广。

Abstract:
Objective This study aimed to observe the curative effect and adverse reaction of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer.
Methods Atotal of 83 patients with inoperable and recurrent advanced ovarian cancer were randomly divided into two groups: hyperthermia group and control group. The hyperthermia group consisted of 42 cases of docetaxel chemotherapy immediately treated with intraperitoneal cisplatin chemotherapy combined with abdominal local hyperthermia. The control group included 41 cases of docetaxel chemotherapy and intraperitoneal cisplatin chemotherapy treatment only.
Results The total efficiencies of the hyperthermia treatment group and the control group were 81% and 58.1%, respectively, which showed that the total efficiency significantly improved (P < 0.05). The ascite control rates were 78.3% and 66.7% and CA125 decreased by 84.2% and 61.5% for the hyperthermia and control groups, respectively. The main adverse reactions were gastrointestinal reaction and bone marrow suppression. However, differences were not statistically significant.
Conclusion Docetaxel combined with cisplatin intraperitoneal perfusion hyperthermia significantly improved the curative effect on advanced ovarian cancer without increasing toxicity, which indicates that it is a treatment worth popularizing.

HTML全文

参考文献(20)

施引文献

资源附件(0)